If you have been reading about prothymosin alpha and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-04-26. Numbers and descriptions here follow the published literature rather than marketing material.
Thymosin alpha 1 is approved as a medicine in several countries, including Italy and China, for indications such as chronic hepatitis B and as an immune adjuvant. It is not approved by the United States Food and Drug Administration as a therapeutic product. In research settings the peptide appears in studies of sepsis, vaccine response, and oncology support, often with mixed or inconclusive results. The evidence base is uneven, and reviews note that many trials were small. Regulatory status therefore differs widely between jurisdictions.
Thymosin alpha 1 is a synthetic 28-amino-acid peptide first isolated in 1966 from thymosin fraction 5, a bovine thymus extract. Its chain begins with an acetylated serine residue and ends with asparagine. The native peptide carries a molecular mass near 3,108 daltons. Researchers classify it as an immunomodulatory agent rather than a hormone with a single endocrine target. Early work framed it as a thymus-derived factor that supports T-cell maturation. The synthetic form used in research and clinical products matches the natural sequence.
Immune signaling studies link thymosin alpha 1 to Toll-like receptor pathways, particularly TLR2 and TLR9, on dendritic cells and other antigen-presenting cells. Activation of these receptors promotes maturation of T cells and increases natural killer cell activity. The peptide shifts cytokine output toward a T helper 1 profile, raising interferon gamma and interleukin 2 while modulating interleukin 10. Whether these effects translate into clinical benefit for any specific disease remains a subject of debate. Reported outcomes vary across trials and populations.
Laboratory work indicates that the peptide acts on cells of both the innate and adaptive immune systems. Reported effects include signalling through Toll-like receptors on dendritic cells, enhanced T-cell maturation, and increased natural killer cell activity. These actions are described largely from cell-culture and animal experiments, and the precise receptor-level events remain incompletely defined. Studies in humans have generally measured immune markers rather than a single defined molecular target. The resulting picture remains partly descriptive.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Results across trials have been mixed, and several studies were small or conducted under differing protocols. Regulatory status varies by country, and the compound is not approved in every jurisdiction where it is studied. Evidence for any single indication should be read with attention to sample size and endpoint choice.
Thymosin alpha-1 is a 28-residue peptide first isolated from thymus tissue in the 1970s. It corresponds to the N-terminal portion of thymosin beta-4, from which it is cleaved in vivo. The peptide carries an acetyl group at its N-terminus, a modification that affects its charge and stability. Synthetic material produced by solid-phase peptide synthesis is chemically identical to the natural fragment and is the form used in research and clinical studies.
| Property | Value | Notes |
|---|---|---|
| Molecular mass | ≈3,108 Da | Synthetic 28-residue peptide |
| Amino acid count | 28 | N-terminal serine carries an acetyl group |
| Appearance | White to off-white powder | Lyophilized solid |
| Water solubility | Freely soluble | Dissolves in aqueous buffer |
| Common synonyms | Thymalfasin; Tα1 | Thymalfasin is the international nonproprietary name |
Thymosin beta-4 is a separate 43-residue peptide that binds actin and participates in cell migration; it shares no sequence similarity with thymosin alpha-1 despite the common family name. Other preparative materials, such as thymosin fraction 5 and thymopoietin, contain distinct mixtures or peptides. The shared thymosin label reflects the tissue of origin used in early purification, not a common structural core. Treating these molecules as interchangeable is a frequent source of confusion in laboratory reports and in popular summaries alike.
Thymosin alpha-1 is a synthetic peptide of 28 amino acid residues that corresponds to a naturally occurring fragment first isolated from thymus tissue. Its chain is acetylated at the amino terminus, a modification that shields the peptide from rapid cleavage by aminopeptidases. The molecule carries a net negative charge at physiological pH and dissolves freely in water. Researchers classify it as an immune-modulating agent rather than a classical hormone, because it acts on several cell types of both the innate and the adaptive immune system.
Whether the free 28-residue peptide circulates in human tissue remains debated. The best-documented human source is prothymosin alpha, a larger acidic protein that carries the sequence at its N-terminus. Reports of measurable peptide levels in serum and lymphoid tissue exist, yet some of that signal may come from cross-reacting fragments or from the parent protein. Most reviews therefore treat prothymosin alpha as the established human molecule and describe independent circulation of the small peptide as an unresolved question.
Immunological studies connect the peptide to multiple parts of the immune response. It has been reported to engage Toll-like receptor signaling, to promote dendritic cell maturation, and to influence the balance of T helper cell subsets. Changes in natural killer cell activity and in cytokine release appear in cell culture and animal models. These observations describe broad immunomodulatory behavior rather than a single defined receptor target, and the primary molecular interaction has not been settled.
Overall evidence quality varies considerably. A large share of published reports come from single centers, rely on surrogate immunological markers, or lack adequate control groups. Systematic reviews have highlighted this heterogeneity as a barrier to pooling results. Open questions include which patients, if any, might benefit, what treatment duration is appropriate, and whether any effect is independent of standard care. The peptide is often described as an immune modulator rather than a therapy for one disease, which complicates confirmatory trial design.
Thymosin alpha 1 was identified in 1977 as a component of thymosin fraction 5, a heterogeneous preparation used in early studies of thymic function. Investigators purified the active material and determined its amino acid sequence, which enabled chemical synthesis. Work in the following decades concentrated on T-cell maturation and immune reconstitution in animals and small human cohorts. Early preparations varied in composition, so results from that period are difficult to compare with studies using defined synthetic peptide.
Early work on thymic extracts in the 1960s described a heat-stable acidic fraction containing many polypeptides. Separation of that mixture yielded individual components, and thymosin alpha-1 was named as one of them on the basis of assays for T-cell activity. The first preparations came from calf thymus, while subsequent research and clinical material has been chemically synthesized. Nomenclature in older papers is inconsistent, and the same peptide sometimes appears under different designations, which complicates literature searches.
Most published studies on thymosin alpha-1 report changes in immune measurements rather than clinical outcomes, and findings differ across designs and populations. Whether the peptide signals through one defined receptor or through several less specific interactions remains an open question. Its reported circulation half-life of a few hours complicates comparison of dosing schedules across trials. Mechanistic claims are frequently drawn from isolated cell cultures, and how far those results extend to whole organisms is unresolved.
Automated synthesis systems are laboratory robots that combine of software and hardware. As synthesis is a linear combination of steps, the individual steps can be modularized into hardware that accomplishes the specific step (mixing, heating or cooling, product analysis, etc.). Such hardware includes robotic arms that use dispensers and grippers to transfer materials and shakers that adjust the stirring speed and cartesian coordinate system robots that operate on a X Y Z axis and can move items and perform synthesis within designated bounds. Conditions of reactions (atmosphere, temperature, pressure) are controlled with the help of peripherals like: gas cylinders, vacuum pump, reflux system and cryostat. Modular platforms use a variety of tools in order to perform all the unit operations needed in synthesis. There are many commercial modular hardware solutions available to execute synthesis. New software programs are available that can compile an automated synthesis procedure in executable code directly from existing literature. There are also software programs that can retro-synthetically generate a procedure at the level of proficiency of a graduate student.
The game's scope suffered from content not being removed when necessary; other components would be endlessly refined without being finalized, preventing the developers from focusing on other parts of the game system. All content additionally required approval by White Wolf and Activision. After three years of development, the game was progressing slowly, and it was unknown when it would be finished. Activision set a series of deadlines for the project's development to ensure Troika had sufficient time to effectively test the game, though these milestones were repeatedly extended, and Bloodlines eventually ran over budget. In 2003 Activision intervened, ordering that the game be ready for release in the next few months and even advancing more money to Troika to complete its work on The Temple of Elemental Evil for Atari, freeing the Troika team to work on Bloodlines exclusively. Activision eventually issued an ultimatum that the project be finished within months, on September 15, 2004. Troika delivered a version of Bloodlines on the required date; due to its scale, the game underwent three weeks of testing. Activision decided that the game was suitable for release but was contractually bound to withhold Bloodlines until after the debut of Half-Life 2 in November 2004. Troika convinced Activision to use the delay to fund further development; the additional budget was insufficient to pay all of Troika's staff, and some employees worked unpaid to complete the project.
== Interactions == Interactions are important for SGLT2 inhibitors because most people with type 2 diabetes are taking many other medications. Gliflozins appear to increase the diuretic effect of thiazides, loop diuretics and related diuretics and may increase the risk of dehydration and hypotension. It is important to adjust the dose of antidiabetics if the treatment is combination therapy to avoid hypoglycemia. For example, interactions with sulfonylureas have led to severe hypoglycemia presumably due to cytochrome P450.
F(ab')2, and to a greater extent Fab, fragments allow more exact localization of the target antigen, i.e., in staining tissue for electron microscopy. The divalency of the F(ab')2 fragment enables it to cross-link antigens, allowing use for precipitation assays, cellular aggregation via surface antigens, or rosetting assays.
Sources: en.wikipedia.org
=== Pregnancy === It is possible that relaxin in the placenta could be a contributing factor to inducing labour in humans and therefore serum relaxin levels during pregnancy have been linked to premature birth.
given a Literature prize from the city of Zurich, 1932 made Titular Professor of the Swiss Federal Institute of Technology in Zurich, ETH 1935 appointed Honorary Member of the Royal Society of Medicine 1939 given a Festschrift at Eranos 1945 appointed President of the Society of Analytical Psychology, London, 1946 given a Festschrift by students and friends in 1955 named Honorary citizen of Küsnacht 1960, on his 85th birthday
In the 1580s, under the direction of Thomas Digges and championed by Sir Walter Raleigh, early port infrastructure work commenced to address siltation through the use of sluices and the development of an enclosed pool of water known as the Great Pent, by means of which the harbour could be periodically scoured. The Great Pent was formed by the construction of a cross wall across the existing natural shingle lagoon at the mouth of the River Dour: the work was largely undertaken by labourers from Romney Marsh, using skills honed in the construction of seawalls. The project has been described as "one of the most successful engineering enterprises of [Queen] Elizabeth's reign". The later construction of Wellington Dock, designed by James Walker in the early 1830s, occupies the approximate footprint of the Great Pent. After the threats of the Napoleonic Wars at the beginning of the 19th century, the Admiralty selected Dover as the most suitable location of a harbour of refuge for the fleet between the dockyards of Chatham and Portsmouth. In 1847 construction began on the Admiralty Pier. Envisaged as the Western Arm of the proposed haven, completion of the massive first stage in 1871 effectively stopped the silting of the harbour mouth as it cut off the drift of shingle from the direction of Folkestone. The Admiralty Pier was constructed using a foundation of Portland stone blocks surmounted by granite and durable Bramley Fall stone on the seaward facing exterior. Stothert & Pitt's 1885 Price Book records Messers H.
. The origin of this minimum conductivity is still unclear. However, rippling of the graphene sheet or ionized impurities in the SiO2 substrate may lead to local puddles of carriers that allow conduction. Several theories suggest that the minimum conductivity should be
Autoimmune disorder, such as systemic lupus erythematosus (SLE), rheumatoid arthritis, and Sjögren's syndrome Chronic liver disease, such as cirrhosis Certain medications, including thiazide diuretics and opiates Genetic factors: There may be a genetic component
Sources: en.wikipedia.org
The charge-to-mass ratio (Q/m) of an object is, as its name implies, the charge of an object divided by the mass of the same object. This quantity is generally useful only for objects that may be treated as particles. For extended objects, total charge, charge density, total mass, and mass density are often more useful. Derivation:
The vacuum flask consists of two vessels, one placed within the other and joined at the neck. The gap between the two vessels is partially evacuated of air, creating a partial-vacuum which reduces heat conduction or convection. Heat transfer by thermal radiation may be minimized by silvering flask surfaces facing the gap but can become problematic if the flask's contents or surroundings are very hot; hence vacuum flasks usually hold contents below the boiling point of water. Most heat transfer occurs through the neck and opening of the flask, where there is no vacuum. Vacuum flasks are usually made of metal, borosilicate glass, foam or plastic and have their opening stoppered with cork or polyethylene plastic. Vacuum flasks are often used as insulated shipping containers. Extremely large or long vacuum flasks sometimes cannot fully support the inner flask from the neck alone, so additional support is provided by spacers between the interior and exterior shell. These spacers act as a thermal bridge and partially reduce the insulating properties of the flask around the area where the spacer contacts the interior surface. Several technological applications, such as NMR and MRI machines, rely on the use of double vacuum flasks. These flasks have two vacuum sections. The inner flask contains liquid helium and the outer flask contains liquid nitrogen, with one vacuum section in between. The loss of precious helium is limited in this way.
The dragonless Aemond claims Vhagar, which leads to a fight between Alicent and Rhaenyra's children where Luke slashes one of Aemond's eyes out. They are all brought before Viserys in a mass gathering, where a furious Alicent demands one of Luke's eyes to be taken out as retribution, arguing with Rhaenyra who defends her kids. After Viserys refuses to abide by Alicent's demand, she grabs his Valyrian steel dagger and rushes towards Luke, but is blocked by Rhaenyra. Aemond asserts that the loss of his eye in exchange for gaining a dragon was a fair trade, and Viserys considers the matter settled under those conditions. He also declares that anyone claiming Rhaenyra's children to be bastards will lose their tongue. Viserys reinstates Otto as his Hand (as Lyonel had recently perished in a fire), where he and Alicent conspire to solidify their family's positions at court while Rhaenyra and Daemon unite to counter their influence over the court. Six years later, Viserys' health has greatly declined, as his face is partially disfigured and he is frequently bedridden. Otto and Alicent have de facto control over royal matters, as Viserys frequently drinks milk of the poppy and has declining mental acuity. Corlys' younger brother Vaemond petitions the crown to be named as Corlys' heir instead of Luke, who he accuses of being a bastard. Otto presides over the matter and is inclined to rule against Luke, but a frail Viserys shows up to the throne room to oversee the matter himself, walking to the Iron Throne with great difficulty and support from Daemon.
== Clinical significance == In humans, MIA3 was first discovered as an important constituent in the growth and adhesion in melanoma cells. As it is secreted from both chondrocytes and melanoma cells, it also plays a role in the metastasis of melanomas as well as cartilage development. It has been established that melanoma inhibitory gene family members serve several tumor-related functions that are subjected to a variety of human malignancies.
Sources: en.wikipedia.org
It is a chain of 28 amino acids, with an acetyl group attached to the first serine residue. The synthetic version replicates this sequence. Its molecular mass is about 3,108 daltons.
It is usually described as an immunomodulatory peptide rather than a classic hormone. It acts on immune cells through receptor pathways. No single endocrine organ target defines its function.
Several countries, including Italy and China, allow it for specific indications. The FDA has not approved it as a drug in the United States. Availability depends on local regulation.
It corresponds to the first 28 amino acids of thymosin beta-4, a larger protein found in many tissues. The fragment is acetylated at its N-terminus and is produced synthetically for research and pharmaceutical use. Synthetic and natural forms share the same sequence.